Smart switch: new drug combo for breast cancer patients who Don't respond to first treatment
NCT ID NCT07340398
First seen Jan 14, 2026 · Last updated May 20, 2026 · Updated 20 times
Summary
This study tests a personalized approach for people with HER2-positive early breast cancer. After initial treatment, those who don't respond well will switch to a stronger drug combination. The goal is to improve the chance of eliminating all cancer before surgery, while reducing side effects for those who respond well. About 200 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE EARLY BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.